Patents by Inventor David Brittelli

David Brittelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060270702
    Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents.
    Type: Application
    Filed: May 2, 2006
    Publication date: November 30, 2006
    Inventors: Scott Mitchell, Mihaela Danca, Peter Blomgren, David Brittelli, Pavel Zhichkin, Matthew Voss
  • Publication number: 20060229337
    Abstract: At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Application
    Filed: March 9, 2006
    Publication date: October 12, 2006
    Inventors: David Brittelli, Kevin Currie, James Darrow, Jeffrey Kropf, Seung Lee, Steven Gallion, Scott Mitchell, Douglas Pippin, Peter Blomgren
  • Publication number: 20060199846
    Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma.
    Type: Application
    Filed: January 13, 2006
    Publication date: September 7, 2006
    Inventors: Scott Mitchell, Mihaela Danca, Peter Blomgren, Robert DeSimone, Douglas Pippin, David Brittelli
  • Publication number: 20060004011
    Abstract: This invention relates to a compound of Formula I (I) and its use in treating hyper-proliferative disorders and diseases associated with angiogenesis.
    Type: Application
    Filed: November 10, 2003
    Publication date: January 5, 2006
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan Ladouceur, Brian Bear, Cheng Bi, David Brittelli, Michael Burke, Gang Chen, James Cook, Jacques Dumas, Robert Sibley, Michael Turner
  • Publication number: 20050267102
    Abstract: Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formulas: wherein r is 0-2, T is selected from and R40 is a mono- or bi-heterocyclic structure. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, comeal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibularjoint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture.
    Type: Application
    Filed: June 27, 2005
    Publication date: December 1, 2005
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Michael VanZandt, David Brittelli, Brian Dixon